Emergent BioSolutions (EBS) EBIT (2011 - 2026)

Emergent BioSolutions' EBIT history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, EBIT fell 78.96% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $60.7 million (up 161.56% YoY), while the FY2025 annual figure was $100.1 million, up 192.09% from the prior year.
• EBIT was $10.5 million for Q1 2026 at Emergent BioSolutions, up from -$27.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $76.5 million in Q3 2025 to a low of -$292.9 million in Q2 2023.
• Historically, EBIT has averaged -$52.6 million across 5 years, with a median of -$27.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: EBIT slumped 2239.13% in 2023, then jumped 126.96% in 2024.
• A 5-year view of EBIT shows it stood at -$55.3 million in 2022, then advanced by 20.8% to -$43.8 million in 2023, then soared by 78.31% to -$9.5 million in 2024, then plunged by 193.68% to -$27.9 million in 2025, then surged by 137.63% to $10.5 million in 2026.
• The last three EBIT figures came in at $10.5 million (Q1 2026), -$27.9 million (Q4 2025), and $76.5 million (Q3 2025), per Business Quant data.